Skip to main content
Top
Literature
2.
go back to reference Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ. Antiendomysium and antigliadin antibodies in untreated celiacs: disappointing in clinical practice. Am J Gastroenterol. 1999;94:888–94.CrossRefPubMed Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ. Antiendomysium and antigliadin antibodies in untreated celiacs: disappointing in clinical practice. Am J Gastroenterol. 1999;94:888–94.CrossRefPubMed
3.
go back to reference Dickey W, McMillan SA, Hughes DF. Sensitivity of serum tissue transglutaminase antibodies for endomysial antibody positive and negative coeliac disease. Scand J Gastroenterol. 2001;36:511–4.CrossRefPubMed Dickey W, McMillan SA, Hughes DF. Sensitivity of serum tissue transglutaminase antibodies for endomysial antibody positive and negative coeliac disease. Scand J Gastroenterol. 2001;36:511–4.CrossRefPubMed
4.
5.
go back to reference Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217–25.CrossRefPubMed Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217–25.CrossRefPubMed
6.
go back to reference Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–76.CrossRefPubMedCentralPubMed Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–76.CrossRefPubMedCentralPubMed
7.
go back to reference Feng JF, Huang Y, Chen QX. Preoperative platelet to lymphocyte ratio (PLR) is superior to neutrophil to lymphocyte ratio as predictive factor in patients with esophageal squamous carcinoma. World J Surg Oncol. 2014;19:58.CrossRef Feng JF, Huang Y, Chen QX. Preoperative platelet to lymphocyte ratio (PLR) is superior to neutrophil to lymphocyte ratio as predictive factor in patients with esophageal squamous carcinoma. World J Surg Oncol. 2014;19:58.CrossRef
9.
go back to reference Ghoshal K, Bhattacharya M. Overview of platelet physiology: its hemostatic and non-hemostatic role in disease pathogenesis. Sci World J. 2014;2014:781857.CrossRef Ghoshal K, Bhattacharya M. Overview of platelet physiology: its hemostatic and non-hemostatic role in disease pathogenesis. Sci World J. 2014;2014:781857.CrossRef
10.
go back to reference Marsh MN. Studies of intestinal lymphoid tissue. XI–The immunopathology of cell-mediated reactions in gluten sensitivity and other enteropathies. Scanning Microsc. 1988;2:1663–84.PubMed Marsh MN. Studies of intestinal lymphoid tissue. XI–The immunopathology of cell-mediated reactions in gluten sensitivity and other enteropathies. Scanning Microsc. 1988;2:1663–84.PubMed
Metadata
Title
Platelet-to-lymphocyte ratio for early diagnosis of celiac disease
Authors
Murat Sarikaya
Zeynal Dogan
Bilal Ergul
Levent Filik
Publication date
01-03-2015
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 2/2015
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-014-0493-8

Other articles of this Issue 2/2015

Indian Journal of Gastroenterology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine